The Medicines Company
) recently announced the presentation and publication of a pooled
analysis of three phase III studies conducted on its antiplatelet
candidate, Cangrelor. The studies compared Cangrelor
(intravenous) to Plavix (clopidogrel - oral) or placebo for the
prevention of clotting complications during and after
percutaneous coronary intervention (PCI).
The data from the pooled analysis of the CHAMPION program was
similar to results from the CHAMPION PHOENIX trial. Cangrelor
significantly cut the odds of the primary composite endpoint of
death, myocardial infarction (MI), ischemia-driven
revascularization (IDR) or stent thrombosis (ST) at 48 hours
after randomization by 19% and stent thrombosis by 41%.
Meanwhile, The Medicines Co. said that the occurrence of
clinically important major bleeding (measured by GUSTO and TIMI
bleeding scales) was not increased with Cangrelor. However,
higher bleeding was observed when more sensitive measures were
used though there was no major difference in the rate of
transfusions. Transient dyspnea was higher with Cangrelor
compared to Plavix.
The pooled analysis was presented at the European Society of
Cardiology and published in
We note that Cangrelor is currently under FDA review with a
response expected in the second quarter of 2014. The Medicines
Co. is looking to get Cangrelor approved for use in patients
undergoing PCI and in patients requiring bridging from oral
antiplatelet therapy to surgery. The Medicines Co. remains on
track to file for EU approval of Cangrelor later this year.
The Medicines Co. currently carries a Zacks Rank #3 (Hold). At
present, companies like
Gilead Sciences Inc.
) look attractive with all three being Zacks Rank #1 (Strong Buy)
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
To read this article on Zacks.com click here.